Evidence map›Paper›PMID 29739486›Full record

Observational studyEpidemiology and infection2018

Outcomes associated with Clostridium difficile infection in patients with chronic liver disease.

Kierra M Dotson, Samuel L Aitken, Amelia K Sofjan, Dhara N Shah, Rajender R Aparasu, Kevin W Garey

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Epidemiology and infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Clinical microbiology reviews · 2024
    Review
  3. COVID-19 andInfectious disease reports · 2023
    Article
  4. Canadian journal of gastroenterology & hepatology · 2022
    Review
  5. World journal of hepatology · 2021
    Article
  6. Review
  7. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021
    Observational
  8. Clinical and experimental gastroenterology · 2021
    Article
  9. Article
  10. Outcomes ofGastroenterology research · 2020
    Article
  11. Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kierra M DotsonUniversity of Houston College of Pharmacy,Houston,TX,USA.
Samuel L AitkenUniversity of Houston College of Pharmacy,Houston,TX,USA.
Amelia K SofjanUniversity of Houston College of Pharmacy,Houston,TX,USA.
Dhara N ShahUniversity of Houston College of Pharmacy,Houston,TX,USA.
Rajender R AparasuUniversity of Houston College of Pharmacy,Houston,TX,USA.
Kevin W GareyUniversity of Houston College of Pharmacy,Houston,TX,USA.ORCID 0000-0003-2063-7503
University of Houston · US

Funding

Decoding Antibiotic-induced Susceptibility to Clostridium difficile InfectionU01AI124290 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BRITTON, ROBERT A, GAREY, KEVIN W · 2016 to 2020
$7.9M
NIAID NIH HHS U01 AI124290
6 · The paper itself

Abstract

Patients with chronic liver disease (CLD) have frequent exposure to Clostridium difficile infection (CDI) risk factors but the incidence and aetiology of CDI on this population is poorly understood. The aim of this study was to assess the incidence, disease presentation and outcomes of CDI in patients with underlying CLD. The Health Care and Utilization Project National Inpatient Sample (HCUP-NIS) 2009 dataset was used to identify patients with CLD who developed CDI along with matched non-CLD patients with CDI. Using the NIS dataset, the incidence rate of CDI was 189.4/10 000 discharges in CLD patients vs. 83.7/10 000 discharges in the non-CLD matched cohort (P < 0.001). Compared with non-CLD, comorbidity-matched controls with CDI, CLD patients with CDI had higher likelihood of in-hospital mortality (8.8% vs. 18.6%, P < 0.001), increased length of stay by 1.19 days (P < 0.001) and increased total costs by $8632 (P < 0.001). In separate analyses using a tertiary case database of hospitalised patients in Houston, Texas (2006-2016) with CLD and CDI (n = 41) compared with patients with CDI but not CLD (n = 111), CLD patients had significantly higher Charlson comorbidity index (P < 0.0001) but similar risk factors for CDI and CDI-related disease presentation compared with non-CLD patients. In conclusion, CDI-related risk factors were almost universally present in the CLD population. CDI resulted in worse outcomes in this population.

Indexed as

AdolescentAdultAgedAged, 80 and overCase-Control StudiesChronic DiseaseClostridium InfectionsFemaleHumansIncidenceLiver DiseasesMaleMiddle AgedOdds RatioPrognosisRetrospective StudiesAnaerobic infectionCDI Clostridium difficile infectionchronic liver diseaseCLD Chronic liver diseaseepidemiologyHCUP-NIS Health Care and Utilization Project National Inpatient Samplemolecular epidemiologyprospective

Identifiers

PMID29739486
PMCPMC6057822
OpenAlexW2802964549

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.